SCHEMBL416144

SCHEMBL416144

COc1ccc(F)cc1CN(C)C(=O)CCCn1cc(-c2ccc(F)cc2C)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 3/20 0.41
HDAC1 Q13547 3/20 0.41
CDK2 P24941 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
HDAC3 O15379 2/20 0.41
PLA2G7 Q13093 3/20 0.39
CTSA P10619 1/20 0.39
PDK2 Q15119 3/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NLRP3 Q96P20 1/20 0.37
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
TACR1 P25103 1/20 0.36
BCHE P06276 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
ACHE P22303 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2486787 0.94 PLA2G7 (0.39) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL2484979 0.89 PLA2G7 (0.41) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL416691 0.89 PLA2G7 (0.46) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL418475 0.86 POLB (0.43) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL413504 0.86 PLA2G7 (0.42) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL415358 0.86 PLA2G7 (0.42) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL416101 0.84 POLB (0.43) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL414385 0.83 PLA2G7 (0.41) CDK9HDAC1CDK2HDAC6HDAC3
SCHEMBL417189 0.83 PLA2G7 (0.47) PLA2G7NLRP3TACR1KMT2A
SCHEMBL416548 0.80 PLA2G7 (0.42) PLA2G7GAATDP1TACR1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US claimed
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 US disclosed
EP-2376431-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2011-10-19 EP disclosed
WO-2010066847-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS CELLVIR (FR) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 CDK9 162/4885HDAC1 1056/4885CDK2 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.